4-AcO-DiPT
Pharmaceutical compound
From Wikipedia, the free encyclopedia
4-AcO-DiPT, also known as 4-acetoxy-N,N-diisopropyltryptamine or as ipracetin, is a psychedelic drug of the tryptamine and 4-hydroxytryptamine families related to 4-AcO-DMT (psilacetin).[1][2] It is taken orally.[1]
- None
 | |
 | |
| Clinical data | |
|---|---|
| Other names | 4-Acetoxy-DiPT; 4-Acetoxy-N,N-diisopropyltryptamine |
| Routes of administration | Oral[1] |
| Drug class | Non-selective serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C18H26N2O2 |
| Molar mass | 302.418 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
The drug is thought to likely be a prodrug of 4-HO-DiPT, which acts as a non-selective serotonin receptor agonist including of the serotonin 5-HT2A receptor.[3][2] It produces psychedelic-like effects in animals.[2]
4-AcO-DiPT was first described in the literature by 1999.[4][1] It was encountered as a novel designer drug in 2005.[2][5][6]
Use and effects
According to Alexander Shulgin in a 2003 literature review, the dose range of 4-AcO-DiPT is 6 to 10 mg orally.[1] For comparison, the dose range of 4-HO-DiPT is listed as 15 to 20 mg in the same review.[1] Other reports of the properties and effects of 4-AcO-DiPT in humans have also been reported in The Entheogen Review.[4]
Interactions
Pharmacology
Pharmacodynamics
4-AcO-DiPT is thought to be likely to function as prodrug of 4-HO-DiPT, although pharmacokinetic studies are still needed to confirm this.[3][2] It acts as a serotonin 5-HT2 receptor agonist, albeit with greatly reduced potency relative to 4-HO-DiPT.[2] The drug produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents.[2]
Chemistry
4-AcO-DiPT is a tryptamine and is structurally similar to 4-HO-DiPT, psilocin (4-HO-DMT), and 4-AcO-DMT (psilacetin).[1][2]
Analogues
Analogues of 4-AcO-DiPT include diisopropyltryptamine (DiPT), 4-HO-DiPT (iprocin), 4-PrO-DiPT, luvesilocin (4-GO-DiPT), 4-AcO-DMT (psilacetin), 4-AcO-DET (ethacetin), 4-AcO-DPT (depracetin), and 4-AcO-DALT (dalcetin), among others.
History
4-AcO-DiPT was first described in the literature by 1999.[4] Subsequently, it was described by Alexander Shulgin in 2003.[1] The drug was encountered as a novel designer drug in 2005.[2][5][6]
Society and culture
Legal status
Denmark
4-AcO-DiPT is added to the list of Schedule B controlled substances.[7]
Japan
4-AcO-DiPT is a controlled substance in Japan.[8]
Sweden
Sveriges riksdags health ministry Statens folkhälsoinstitut classified 4-AcO-DiPT as "health hazard" under the act Lagen om förbud mot vissa hälsofarliga varor (translated Act on the Prohibition of Certain Goods Dangerous to Health) as of Mar 1, 2005, in their regulation SFS 2005:26 listed as 4-acetoxi-N,N-diisopropyltryptamin (4-AcO-DIPT), making it illegal to sell or possess.[9]
United States
4-AcO-DiPT is an unscheduled substance in the United States. Due to similarities to other scheduled tryptamines, such as diethyltryptamine and psilocin, possession may be prosecuted under the Federal Analog Act in the United States.